HTA Planning and Reimbursement Evidence Strategy

Strengthen HTA dossier and strategy to OPTIMIZE HTA Success

Contact Us
HTA Planning & Reimbursement Evidence Strategy

At MORSE Consulting, we leverage our real-world experience, technical skill, and nuanced understanding of the Canadian payer & HTA context to provide expert guidance on HTA assessment and (re)submission strategies throughout your product launch life cycle. As Canada’s leading experts on the pCPA, HTA approach, and pharmaceutical value strategy, we deliver insights into the subtleties of Canadian market influencers and payers’ views on value. Our services include supporting Health Economics and Outcomes Research (HEOR) by providing strategic guidance to strengthen pharmacoeconomic model strategies, informing pipeline clinical trial development, and planning real-world evidence (RWE) to align with both HTA and payer requirements. We also conduct thorough HTA dossier and strategy reviews and facilitate advisory boards with key opinion leaders. With our HTA planning and reimbursement evidence strategy advice, you can navigate and OPTIMIZE the complex HTA landscape with confidence.

  • Pipeline Assessments
  • HTA Assessment & (Re) Submission Strategy
  • Strategy on Pharmacoeconomic Model
  • RWE Planning & Strategy
  • HTA Dossier & Strategy Review
  • Advisory Boards

Early Evidence Assessments

Optimize your pipeline assets with MORSE’s expert HTA and payer-focused evaluations. ​

  • Pipeline Assessments: At MORSE, we help you plan for market access and reimbursement challenges from the early stages of drug development. We evaluate your clinical trial design and evidence generation strategies to ensure they meet the expectations and standards of payers and decision-makers. We also provide strategic guidance on your launch readiness, market dynamics, and value demonstration, based on our extensive knowledge of the Canadian market and stakeholder perspectives. With MORSE, you can optimize your pipeline assets and facilitate smoother adoption of your products.​
  • RWE Planning and Evidence Strategy: MORSE expertly identifies opportunities to address crucial evidence gaps early with innovative real-world evidence (RWE) strategies. Our expert insights and stakeholder perspectives enable planning for additional research with evidence generation vendors to fill in data gaps left by clinical trials and strengthen your value proposition with HTA and payer discussions.​
Market Access Landscape Analysis

HTA Strategy and Planning

Plan for and optimize your submission strategy, ensuring that your product is well-positioned for successful reimbursement​

  • HTA Assessment and (Re) Submission Strategy: MORSE offers expert guidance for HTA submissions and strategy-building, based on a deep understanding of Canadian HTA and payer expectations. We evaluate your product’s strengths, weaknesses, and unique features based on evidence and disease context. We pinpoint factors affecting recommendations, address challenges, refine evidence presentation, manage risks, and improve interactions with reviewers and payers. In the event you receive an HTA recommendation that is not favorable, MORSE can also assist in crafting an effective resubmission strategy addressing key gaps and HTA concerns and evaluate the chances of a successful outcome. Our support covers the full HTA process, from planning to informing complex agreements, to showcase the value of your innovative therapies.​
  • Advisory Boards: MORSE designs and facilitates strategic advisory board sessions with key Canadian experts, amplifying your product’s value proposition. Our deep market insights guide the entire process—from planning to post-analysis—ensuring discussions yield actionable insights that resonate within the Canadian health system context. Our advisors actively participate in advisory sessions to offer our unique HTA and payer insights on Canadian and global reimbursement strategy.​

Tactical Evaluation and Guidance

Refine your product positioning with actionable recommendations from our in-depth evaluations ​

  • Pharmacoeconomic Modelling Strategy (Global or Local): MORSE combines technical acumen and policy insights to enhance development of robust pharmacoeconomic models and optimize them for the Canadian market. MORSE can strategically support model development with your team or your submission vendor to guide modeling decisions and assumptions with HTA and payer perspectives, while incorporating the best available evidence. We critically appraise reports with our policy expertise to facilitate HTA assessments and positioning for pricing discussions with persuasive rationale and strategic value messaging.​
  • HTA Dossier Review: MORSE provides a meticulous review of your HTA dossier submissions, pinpointing gaps and opportunities for optimal product positioning in the Canadian market. We thoroughly assess draft documents and deliver insights into the subtleties of reviewers’ views on value. We provide detailed feedback and strategic insights to enhance clarity and impact, ensuring your value proposition is compelling. ​
HTA Planning and Reimbursement Evidence Strategy